Management of women with an unexpected low Ovarian response to gonadotropin

Alessandro Conforti, Sandro C. Esteves, Danilo Cimadomo, Alberto Vaiarelli, Francesca Di Rella, Filippo Maria Ubaldi, Fulvio Zullo, Giuseppe De Placido, Carlo Alviggi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

POSEIDON groups 1 and 2 patients respond poorly (<4 oocytes retrieved) or sub-optimally (4–9 oocytes retrieved) to gonadotropin stimulation despite the presence of adequate ovarian parameters, which negatively affect their cumulative chances of delivering a baby using Assisted Reproductive Technology. A polygenic trait involving gonadotropins and/or their receptors seems to be the primary pathophysiology mechanism explaining this phenomenon. The clinical management is mainly focused on maximizing oocyte yield as to increase the likelihood of having at least one euploid embryo for transfer. Indices such as FORT (follicle output rate) and FOI (follicle-to-oocyte index) may be used to determine if the ovarian reserve was properly explored during a previous ovarian stimulation. Testing for the presence of common polymorphisms affecting gonadotropins and/or their receptors can also be considered to identify patients at risk of hypo-response. An individualized estimation of the minimum number of oocytes needed to obtain at least one euploid embryo can assist counseling and treatment planning. Among currently existing pharmacological interventions, use of recombinant FSH in preference over urinary gonadotropin preparations, FSH dosage increase, and use of rLH supplementation may be considered -alone or combined- for optimally managing POSEIDON’s groups 1 and 2 patients. However, given the recent introduction of the POSEIDON criteria, there is still a lack of studies examining the role of interventions specifically to patients classified as groups 1 and 2, thus making it an area for open research.

Original languageEnglish
JournalFrontiers in Endocrinology
Volume10
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Gonadotropins
Oocytes
Multifactorial Inheritance
Assisted Reproductive Techniques
Ovulation Induction
Embryo Transfer
Counseling
Embryonic Structures
Pharmacology
Research
Therapeutics

Keywords

  • ART calculato
  • Assisted Reproductive Technology
  • Follicleto-oocyte index
  • Hypo-response
  • Ovarian reserve
  • Ovarian stimulation
  • POSEIDON criteria
  • Suboptimal response

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Conforti, A., Esteves, S. C., Cimadomo, D., Vaiarelli, A., Di Rella, F., Ubaldi, F. M., ... Alviggi, C. (2019). Management of women with an unexpected low Ovarian response to gonadotropin. Frontiers in Endocrinology, 10. https://doi.org/10.3389/fendo.2019.00387

Management of women with an unexpected low Ovarian response to gonadotropin. / Conforti, Alessandro; Esteves, Sandro C.; Cimadomo, Danilo; Vaiarelli, Alberto; Di Rella, Francesca; Ubaldi, Filippo Maria; Zullo, Fulvio; De Placido, Giuseppe; Alviggi, Carlo.

In: Frontiers in Endocrinology, Vol. 10, 01.06.2019.

Research output: Contribution to journalReview article

Conforti, A, Esteves, SC, Cimadomo, D, Vaiarelli, A, Di Rella, F, Ubaldi, FM, Zullo, F, De Placido, G & Alviggi, C 2019, 'Management of women with an unexpected low Ovarian response to gonadotropin', Frontiers in Endocrinology, vol. 10. https://doi.org/10.3389/fendo.2019.00387
Conforti, Alessandro ; Esteves, Sandro C. ; Cimadomo, Danilo ; Vaiarelli, Alberto ; Di Rella, Francesca ; Ubaldi, Filippo Maria ; Zullo, Fulvio ; De Placido, Giuseppe ; Alviggi, Carlo. / Management of women with an unexpected low Ovarian response to gonadotropin. In: Frontiers in Endocrinology. 2019 ; Vol. 10.
@article{0942711dc757456eb7d416cad101ec44,
title = "Management of women with an unexpected low Ovarian response to gonadotropin",
abstract = "POSEIDON groups 1 and 2 patients respond poorly (<4 oocytes retrieved) or sub-optimally (4–9 oocytes retrieved) to gonadotropin stimulation despite the presence of adequate ovarian parameters, which negatively affect their cumulative chances of delivering a baby using Assisted Reproductive Technology. A polygenic trait involving gonadotropins and/or their receptors seems to be the primary pathophysiology mechanism explaining this phenomenon. The clinical management is mainly focused on maximizing oocyte yield as to increase the likelihood of having at least one euploid embryo for transfer. Indices such as FORT (follicle output rate) and FOI (follicle-to-oocyte index) may be used to determine if the ovarian reserve was properly explored during a previous ovarian stimulation. Testing for the presence of common polymorphisms affecting gonadotropins and/or their receptors can also be considered to identify patients at risk of hypo-response. An individualized estimation of the minimum number of oocytes needed to obtain at least one euploid embryo can assist counseling and treatment planning. Among currently existing pharmacological interventions, use of recombinant FSH in preference over urinary gonadotropin preparations, FSH dosage increase, and use of rLH supplementation may be considered -alone or combined- for optimally managing POSEIDON’s groups 1 and 2 patients. However, given the recent introduction of the POSEIDON criteria, there is still a lack of studies examining the role of interventions specifically to patients classified as groups 1 and 2, thus making it an area for open research.",
keywords = "ART calculato, Assisted Reproductive Technology, Follicleto-oocyte index, Hypo-response, Ovarian reserve, Ovarian stimulation, POSEIDON criteria, Suboptimal response",
author = "Alessandro Conforti and Esteves, {Sandro C.} and Danilo Cimadomo and Alberto Vaiarelli and {Di Rella}, Francesca and Ubaldi, {Filippo Maria} and Fulvio Zullo and {De Placido}, Giuseppe and Carlo Alviggi",
year = "2019",
month = "6",
day = "1",
doi = "10.3389/fendo.2019.00387",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Management of women with an unexpected low Ovarian response to gonadotropin

AU - Conforti, Alessandro

AU - Esteves, Sandro C.

AU - Cimadomo, Danilo

AU - Vaiarelli, Alberto

AU - Di Rella, Francesca

AU - Ubaldi, Filippo Maria

AU - Zullo, Fulvio

AU - De Placido, Giuseppe

AU - Alviggi, Carlo

PY - 2019/6/1

Y1 - 2019/6/1

N2 - POSEIDON groups 1 and 2 patients respond poorly (<4 oocytes retrieved) or sub-optimally (4–9 oocytes retrieved) to gonadotropin stimulation despite the presence of adequate ovarian parameters, which negatively affect their cumulative chances of delivering a baby using Assisted Reproductive Technology. A polygenic trait involving gonadotropins and/or their receptors seems to be the primary pathophysiology mechanism explaining this phenomenon. The clinical management is mainly focused on maximizing oocyte yield as to increase the likelihood of having at least one euploid embryo for transfer. Indices such as FORT (follicle output rate) and FOI (follicle-to-oocyte index) may be used to determine if the ovarian reserve was properly explored during a previous ovarian stimulation. Testing for the presence of common polymorphisms affecting gonadotropins and/or their receptors can also be considered to identify patients at risk of hypo-response. An individualized estimation of the minimum number of oocytes needed to obtain at least one euploid embryo can assist counseling and treatment planning. Among currently existing pharmacological interventions, use of recombinant FSH in preference over urinary gonadotropin preparations, FSH dosage increase, and use of rLH supplementation may be considered -alone or combined- for optimally managing POSEIDON’s groups 1 and 2 patients. However, given the recent introduction of the POSEIDON criteria, there is still a lack of studies examining the role of interventions specifically to patients classified as groups 1 and 2, thus making it an area for open research.

AB - POSEIDON groups 1 and 2 patients respond poorly (<4 oocytes retrieved) or sub-optimally (4–9 oocytes retrieved) to gonadotropin stimulation despite the presence of adequate ovarian parameters, which negatively affect their cumulative chances of delivering a baby using Assisted Reproductive Technology. A polygenic trait involving gonadotropins and/or their receptors seems to be the primary pathophysiology mechanism explaining this phenomenon. The clinical management is mainly focused on maximizing oocyte yield as to increase the likelihood of having at least one euploid embryo for transfer. Indices such as FORT (follicle output rate) and FOI (follicle-to-oocyte index) may be used to determine if the ovarian reserve was properly explored during a previous ovarian stimulation. Testing for the presence of common polymorphisms affecting gonadotropins and/or their receptors can also be considered to identify patients at risk of hypo-response. An individualized estimation of the minimum number of oocytes needed to obtain at least one euploid embryo can assist counseling and treatment planning. Among currently existing pharmacological interventions, use of recombinant FSH in preference over urinary gonadotropin preparations, FSH dosage increase, and use of rLH supplementation may be considered -alone or combined- for optimally managing POSEIDON’s groups 1 and 2 patients. However, given the recent introduction of the POSEIDON criteria, there is still a lack of studies examining the role of interventions specifically to patients classified as groups 1 and 2, thus making it an area for open research.

KW - ART calculato

KW - Assisted Reproductive Technology

KW - Follicleto-oocyte index

KW - Hypo-response

KW - Ovarian reserve

KW - Ovarian stimulation

KW - POSEIDON criteria

KW - Suboptimal response

UR - http://www.scopus.com/inward/record.url?scp=85070401968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070401968&partnerID=8YFLogxK

U2 - 10.3389/fendo.2019.00387

DO - 10.3389/fendo.2019.00387

M3 - Review article

AN - SCOPUS:85070401968

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

ER -